印度Nicholas Piramal India Limited 
Nicholas Piramal印度有限公司（印度Mumbia）的委托生产部门NPIL Pharma公司在2005年收购了Avecia制药公司，正在试图发展成为最大的三家委托合成公司之一。

对于NPIL Pharma 公司来说2006年最优先要走做的事情是在完成早先进行的收购后将Avecia公司的委托化学合成和药物生产服务业务整合进来。通过这次收购，NPIL Pharma公司获得三个商业部门：1、早期交付小组，位于英国Huddersfield，致力于I期和II期临床试验产品的委托合成；2、药物产品部门，位于英国的Huddersfield和Billingham，致力于扩大并生产后期中间体和API，用于III期临床试验和产品上市销售；3、高效底物部门，位于苏格兰的Grangemouth，致力于研发、扩大和生产高效前列腺素和细胞毒API。NPIL Pharma做为收购Avecia公司的一部分，公司还拥有了Avecia公司的子公司Torcan Chemical公司，该公司位于加拿大安大略Aurora，致力于临床前和早期临床试验产品开发。同时，公司还获得了Reaxa公司（英国曼彻斯特，）25％的股票，该公司致力于催化技术，也创立于Avecia公司。

Avecia公司的资产将被整合进NPIL Pharma公司的资产中，NPIL Pharma公司在印度拥有4个生产部门，包括Mumbai和Chennai的研发实验室，Chennai的GMP车间，Hyderabad的大规模车间。

收购Avecia公司是NPIL公司在委托合成领域内的第一个收购行为，NPIL Pharma公司现在正在向全球大型委托合成企业方向迈出一大步，成为少数几个将API/中间体开发和生产整合到一起形成最终剂型药物的委托生产企业中的一个。

NPIL Pharma公司是Nicholas Piraml印度有限公司的一部分，Nicholas Piraml印度有限公司是印度第四大制药保健公司，2005年收入达到2亿9100万美元。

Nicholas Piramal India Limited is one of India's largest companies with an unmatched record of managing JVs/Alliances/Partnerships, and a proven commitment to IPR. With strong brand management and sales capabilities, a US FDA site-approved plant for on-and-off patent APIs and Intermediates, Basic Research, Process Innovation, Custom Chemical Synthesis, Formulations R&D, NDDS, and a world-class, accredited Clinical Research Organisation, NPIL is poised to emerge as India's pharma powerhouse.

With growth fuelled through a strategy of partnerships, quality acquisitions, brand building, focused selling and manufacturing, NPIL's consolidated net sales turnover was US$ 313 million (INR 14.1 billion) in 2005-06 (April to March)".

NPIL has emerged among the leaders in Indian pharma with a unique mix of inorganic and organic growth fuelled through a strategy of acquisitions, brand building and focused selling, and manufacturing. The company has one of the widest product portfolios in India, spanning nine key therapeutic areas, including the Cardio-vascular, Neuro-psychiatry, Oncology, Diabetes Management, Respiratory, Anti-infectives, Gastro-intestinals, Dermatology and NSAIDS.

The company was formed when the Piramal Group acquired Nicholas Laboratories, a small formulations company in 1988 from Sara Lee. It has followed a multi-pronged strategy to integrate and maximize synergies with the planned acquisitions and develop and consolidate its major strength in marketing to therapeutic niches.

Managed by a team of highly proficient industry professionals, NPIL's key strengths come from its strong brand building, selling and distribution, manufacturing and alliance/partnership management skills. The last, especially, are quite unique in the Indian context - few Indian Pharmaceutical have exhibited such a strong and consistent record in successfully and ethically managing JVs/Alliances and Partnerships as NPIL has.

Its policy of respecting IPR and managing partnerships, in keeping with both the letter and the spirit of written agreements, has been widely respected and commended by its partners.

NPIL is the flagship company of the Rs. 2500 crore (US $ 550 million) Piramal Enterprises (PEL), one of India's largest diversified business houses.